Ads
related to: plaque psoriasis
Search results
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 2 days ago(guselkumab) as a maintenance therapy in patients with moderate to severe active ulcerative colitis....
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 2 days ago“We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 2 days ago“We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S...
India's Sun Pharma beats Q4 profit view on strong US, domestic sales
Reuters· 16 hours agoIndian drugmaker Sun Pharmaceutical Industries posted fourth-quarter profit above estimates on...
Maintenance Tx With Guselkumab for UC Meets All Endpoints
Medscape· 22 hours agoGuselkumab (Tremfya, Janssen/Johnson & Johnson) was superior to placebo for maintenance therapy in...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 3 days agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...
Alvotech (ALVO) Scheduled to Post Quarterly Earnings on Tuesday
ETF DAILY NEWS· 4 days agoAlvotech (NYSE:ALVO – Get Free Report) will post its quarterly earnings results after the market closes on Tuesday, May 21st. Individual interested in participating in the company’s earnings ...
State board targets six prescription drugs to review for affordability for Marylanders
Maryland Matters via Yahoo News· 2 days agoThe board will seek public comments, additional information and data over the next 60 days to...
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...
Tri-County Times· 6 days ago- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)
AbbVie (NYSE:ABBV) Now Covered by Cantor Fitzgerald
ETF DAILY NEWS· 4 days agoCantor Fitzgerald assumed coverage on shares of AbbVie (NYSE:ABBV – Get Free Report) in a research note issued to investors on Friday, MarketBeat.com reports. Cantor Fitzgerald’s price objective ...
Ads
related to: plaque psoriasis
